In this cohort study, baseline serum KL-6 levels were higher in patients with IPF with lung cancer than in those without lung cancer, and an elevation in serum KL-6 levels was correlated with a significant decline in FVC during follow-up. The gene discussed is MUC1; the disease is lung carcinoma.